Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bayer AG is conducting a clinical study titled An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria. The study aims to assess the long-term safety and efficacy of finerenone, a drug intended to manage chronic kidney disease (CKD) in children and young adults by controlling proteinuria and hypertension.
The intervention being tested is finerenone, marketed as Kerendia, which is expected to work alongside ACE inhibitors or angiotensin receptor blockers to better regulate the renin-angiotensin-aldosterone system, potentially improving kidney function in patients with CKD.
This Phase 3 study is interventional with a single-group assignment. It is open-label, meaning there is no masking, and its primary purpose is treatment. Participants will receive finerenone for up to 18 months, with regular monitoring of health indicators.
The study began on November 8, 2022, and is currently recruiting participants. The primary completion and estimated study completion dates are set for July 25, 2025. These timelines are crucial for tracking the progress and potential market entry of the treatment.
The study’s progress could influence Bayer’s stock performance as successful results may enhance investor confidence and market position, especially in the competitive pharmaceutical landscape focusing on CKD treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.